This page provides an independent statistical analysis and educational interpretation of publicly reported results. ClinicalTrials.gov provides the official trial registry record.
1. Trial at a Glance
VALENTINO was a randomized, parallel, open-label phase 2 trial in patients with RAS wild-type, metastatic colorectal cancer. The registry lists 224 participants, two arms, and progression-free survival from enrollment over a 3-year time frame as the primary efficacy endpoint.
| Feature | VALENTINO |
|---|---|
| Phase | Phase 2 |
| Condition | Metastatic Colorectal Cancer |
| Population | Patients with RAS wild-type, metastatic colorectal cancer |
| Design | Randomized, parallel |
| Masking | None |
| Primary purpose | Treatment |
| Enrollment | 224 |
| Number of arms | 2 |
| Primary endpoint | Efficacy in terms of progression-free survival from enrollment |
| Primary endpoint time frame | 3 years |
| Trial status | UNKNOWN |
| Start date | 2015-06 |
| Primary completion date | 2018-07 |
| Lead sponsor | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano |
| Sponsor type | OTHER |
| ClinicalTrials.gov | NCT02476045 |
2. Clinical Question
The clinical question is centered on whether a panitumumab-based maintenance strategy can be evaluated in patients with RAS wild-type, metastatic colorectal cancer using progression-free survival as the primary efficacy outcome.
Population
Patients with RAS wild-type, metastatic colorectal cancer.
Intervention framework
The registry lists panitumumab-based treatment components, including panitumumab and a regimen containing oxaliplatin, 5-fluorouracil, and leucovorin.
Comparator framework
The trial has two randomized arms in a parallel design. The registry lists two intervention configurations but does not provide arm-specific allocation details in the record summarized here.
Primary question
How does the randomized maintenance strategy compare with the alternative strategy with respect to progression-free survival from enrollment over the registered 3-year time frame?
3. Trial Design
Randomization is important statistically because it establishes the treatment assignment mechanism before outcomes are observed. In a parallel randomized design, participants remain associated with their assigned treatment strategy for the primary comparison. The absence of masking means that treatment assignment was not concealed from participants and study personnel in the design described by the registry.
4. Intervention Structure
The registry identifies three intervention entries: 5-fluorouracil, leucovorin, and panitumumab; panitumumab; and oxaliplatin, 5-fluorouracil, leucovorin, and panitumumab. These entries describe the treatment components recorded for the study.
Panitumumab-based strategy
- Panitumumab is listed as an intervention.
- 5-fluorouracil is listed as an intervention.
- Leucovorin is listed as an intervention.
Panitumumab-containing combination
- Panitumumab is listed as an intervention.
- Oxaliplatin is listed as an intervention.
- 5-fluorouracil is listed as an intervention.
- Leucovorin is listed as an intervention.
5. Primary Endpoint
| Endpoint | Registry definition | Time frame |
|---|---|---|
| Efficacy | In terms of progression free survival (from the enrollment) | 3 years |
What the endpoint measures
Progression-free survival is a time-to-event endpoint. Conceptually, it measures the time from the specified starting point to the occurrence of the endpoint event, with participants who have not experienced the event by the end of their available follow-up treated as censored under the applicable analysis rules.
For VALENTINO, the registry explicitly defines the starting point as enrollment and specifies a 3-year time frame. This distinction matters because time-to-event analyses depend on both the event definition and the time origin. Changing the time origin can change the estimand and therefore should not be done casually.
6. Planned Analysis
The registry lists progression-free survival from enrollment as the primary efficacy endpoint over 3 years, but no formal statistical analysis is posted in the ClinicalTrials.gov record.
Primary endpoint
Time origin: enrollment · Registered time frame: 3 years
For a randomized trial with a time-to-event primary endpoint such as progression-free survival, the usual analytical framework is based on estimating the distribution of event times while appropriately handling censoring. A Kaplan-Meier estimator is commonly used to describe the survival function, while a log-rank test can be used to compare randomized groups. A Cox proportional-hazards model is commonly used when a hazard-ratio summary is desired.
The appropriate analysis population is ordinarily tied to the randomized assignment for the primary efficacy comparison. The exact analysis population, censoring rules, treatment-effect measure, hypothesis-testing framework, covariate adjustment, and handling of missing or incomplete follow-up would need to be specified in the trial's statistical analysis plan to establish the precise confirmatory analysis.
7. Statistical Methodology
Time-to-event analysis
Progression-free survival differs from a simple binary endpoint because participants can have different lengths of follow-up. A participant who has not experienced the event at the end of observation still contributes information about remaining event-free up to that point.
The survival function S(t) represents the probability that the event time T exceeds time t. For progression-free survival, the corresponding event-time definition must follow the protocol's operational definition.
Kaplan-Meier estimation
A Kaplan-Meier estimator is a standard descriptive method for progression-free survival. It accommodates right censoring and produces an estimated event-free survival curve over time. This is particularly useful when follow-up differs among randomized participants.
Here di is the number of events at time ti, while ni is the number at risk immediately before that time.
Log-rank comparison
A log-rank test is commonly used to compare time-to-event distributions between randomized groups. It considers the observed and expected number of events at successive event times rather than reducing each participant to a simple yes-or-no outcome.
Cox proportional-hazards model
A Cox model can summarize the relative difference between treatment groups using a hazard ratio. In its basic form, the model relates the hazard at a particular time to treatment assignment and, when appropriate, other covariates.
A hazard ratio below 1 indicates a lower estimated instantaneous event rate in the numerator group relative to the denominator group under the fitted model. It is not itself a probability, risk ratio, median difference, or absolute treatment effect.
Censoring
Censoring is central to progression-free survival analysis. If a participant has not experienced the event when observation ends, the participant's exact future event time is unknown. A valid survival analysis uses the available follow-up without treating that participant as though the event had occurred or as though the participant had necessarily remained event-free indefinitely.
8. Statistical Methods Explained
Why is progression-free survival analyzed as a time-to-event endpoint?
Because the endpoint contains information about when an event occurs, not simply whether it occurs. Two participants can both experience progression while contributing very different amounts of event-free follow-up. A time-to-event method preserves that timing information.
Why use enrollment as the time origin?
The registry defines progression-free survival as being measured from enrollment. The time origin determines how follow-up is aligned across participants and therefore forms part of the estimand. Starting the clock at a different point would define a different analysis.
Why is Kaplan-Meier useful?
Kaplan-Meier estimation provides an intuitive description of the progression-free survival experience over time while accounting for censoring. It can show how the probability of remaining event-free changes throughout follow-up rather than reducing the entire study to one number.
What would a hazard ratio add?
A hazard ratio provides a relative summary of the instantaneous event rates between randomized groups under a Cox model. It can be compact and useful, but it should be interpreted alongside the survival curves and clinically meaningful absolute time-point estimates.
Why does censoring matter?
Censoring determines how much event-time information each participant contributes. The validity of a standard survival analysis depends on appropriate censoring rules and assumptions about the relationship between censoring and the event process.
What does the 3-year time frame mean?
The registry specifies 3 years as the time frame for the primary efficacy endpoint. This identifies the registered observation horizon for progression-free survival; it does not by itself specify a particular statistical test or imply a particular outcome at 3 years.
9. Randomization and Causal Interpretation
Randomization is the central statistical feature that supports a causal comparison between the two treatment strategies. When treatment assignment is randomized, differences in outcomes can be interpreted within the framework created by the randomization rather than as simple associations between treatment received and outcome.
What randomization provides
Random assignment creates treatment groups whose differences can be evaluated under a prespecified allocation mechanism rather than relying solely on observational adjustment.
What randomization does not guarantee
Randomization does not make every baseline characteristic numerically identical, nor does it eliminate uncertainty in the estimated treatment effect.
Why phase 2 matters
A phase 2 randomized trial can provide an important comparative assessment while generally involving a different development context from a definitive phase 3 confirmatory trial.
Why open-label status matters
The registry specifies no masking. Knowledge of treatment assignment can potentially affect behavior, assessment, treatment decisions, or other aspects of trial conduct, depending on the endpoint and safeguards used.
10. Interpreting Progression-Free Survival
Progression-free survival summarizes how event-free time is distributed across a study population. It does not mean that every participant experiences the same event time or that a group-level estimate describes the experience of each individual patient.
A hazard ratio, if reported, would describe a relative comparison of event rates. A Kaplan-Meier estimate at a specified time would instead describe the estimated probability of remaining event-free through that time. These quantities answer related but different questions.
If a formal hypothesis test were performed, its p-value would quantify the compatibility of the observed data with the null hypothesis under the specified testing framework. It would not measure the magnitude of the treatment effect or its clinical importance.
A confidence interval around a treatment-effect estimate would describe uncertainty associated with the estimated effect under the specified statistical model and sampling framework. It would not describe the range of outcomes that individual participants can experience.
11. Proportional-Hazards Considerations
If a Cox proportional-hazards model is used, the hazard ratio is based on a proportional-hazards framework. This assumes that the relative hazard between groups is adequately represented by a constant ratio over the relevant follow-up.
That assumption is distinct from the randomized design itself. Randomization establishes the treatment comparison, while the Cox model introduces a particular mathematical representation of how the event rates relate over time. If hazards vary substantially in their relative separation, a single hazard ratio may not fully describe the treatment-effect pattern.
12. Censoring and Follow-Up
Progression-free survival requires rules for participants whose event status is not observed throughout the entire follow-up period. Such participants are censored at an appropriate time according to the protocol and analysis plan.
| Statistical issue | Why it matters |
|---|---|
| Time origin | The registry specifies enrollment as the starting point for progression-free survival. |
| Event definition | The operational definition of progression-free survival determines which observations count as events. |
| Censoring | Participants without an observed event contribute information through their available follow-up. |
| Follow-up duration | The registry specifies a 3-year time frame for the primary efficacy endpoint. |
| Analysis rules | Exact censoring conventions and analysis populations are not specified in the registry information summarized here. |
These details are not merely technical. A progression-free survival estimate can change depending on how progression, death, treatment discontinuation, loss to follow-up, and other incomplete observations are handled. The analysis plan therefore forms part of the definition of the estimand.
13. Multiplicity and Hypothesis Testing
The registry identifies one registered primary endpoint: efficacy in terms of progression-free survival from enrollment over 3 years. No posted statistical analysis is available to establish a particular alpha level, multiplicity strategy, interim-analysis boundary, or hierarchy among multiple efficacy hypotheses.
Multiplicity becomes important whenever several statistical hypotheses are tested and interpreted together. If multiple primary endpoints, repeated interim looks, subgroup comparisons, or other confirmatory hypotheses are introduced, the overall probability of a false-positive conclusion can differ from the nominal level of any individual test.
Single primary endpoint
The registry identifies progression-free survival as the primary efficacy endpoint.
Multiple analyses
Additional analyses can require an explicit multiplicity framework when they are intended to support confirmatory claims.
14. Interim Analysis and Missing-Data Considerations
The registry information does not specify an interim-analysis schedule or an alpha-spending procedure. It also does not specify statistical imputation methods or detailed rules for handling missing outcome assessments.
For a time-to-event endpoint, missingness is handled differently from a conventional continuous or binary endpoint. Participants can contribute partial follow-up through censoring, but the assumptions governing censoring remain important. If outcome assessments are missed, the protocol-defined rules for determining progression and censoring become particularly relevant.
15. Analysis Populations
The registry information identifies the trial as randomized but does not provide detailed analysis-population definitions. For the primary efficacy comparison, an intention-to-treat framework is commonly used in randomized trials because it preserves the comparison created by random assignment.
| Population concept | Statistical role |
|---|---|
| Randomized population | Provides the population defined by the randomized treatment comparison. |
| Intention-to-treat population | Typically analyzes participants according to randomized assignment for an efficacy comparison. |
| Per-protocol population | May provide a supplementary perspective when adherence to protocol-defined treatment and assessments is relevant, if prespecified. |
| Safety population | Usually defined by actual treatment exposure rather than randomization alone, subject to the protocol and analysis plan. |
These population definitions should not be treated as interchangeable. The randomized treatment comparison and an exposure-based safety summary answer different statistical questions.
16. Safety
The registry information summarized for VALENTINO identifies the interventions and the randomized two-arm design but does not provide serious adverse-event counts by arm. Consequently, no numerical arm-level safety comparison is presented here.
From a statistical perspective, safety is usually summarized using counts and percentages of participants experiencing adverse events, serious adverse events, treatment discontinuations, or other prespecified safety outcomes. The denominator must be clearly defined because randomized, treated, and evaluable populations can differ.
17. Registry Timeline
Trial start
The registry lists June 2015 as the study start date.
Primary completion
The registry lists July 2018 as the primary completion date.
UNKNOWN
The ClinicalTrials.gov record has an UNKNOWN status in the registry information summarized here.
18. Why This Trial Matters Statistically
VALENTINO is a useful teaching example because it combines a randomized comparative design with a time-to-event primary endpoint. That combination illustrates why clinical-trial statistics require more than a simple comparison of percentages.
| Concept | How it appears in VALENTINO |
|---|---|
| Randomization | The registry classifies allocation as randomized. |
| Parallel design | The study uses a parallel design model with two arms. |
| Phase 2 development | The trial is registered as phase 2. |
| Open-label design | Masking is listed as none. |
| Time-to-event endpoint | Progression-free survival is the primary efficacy endpoint. |
| Time origin | The registered progression-free survival endpoint is measured from enrollment. |
| Longitudinal follow-up | The primary endpoint has a registered time frame of 3 years. |
| Censoring | A central statistical issue for progression-free survival analysis. |
| Kaplan-Meier estimation | A standard descriptive approach for time-to-event outcomes. |
| Log-rank testing | A standard method for comparing survival distributions between randomized groups. |
| Cox regression | A standard model for estimating a hazard ratio when appropriate. |
| Interpretation of uncertainty | Confidence intervals and effect measures would be needed to describe precision if results were available. |
19. What a Complete PFS Analysis Would Show
A complete statistical presentation of the primary endpoint would ordinarily begin with the Kaplan-Meier progression-free survival curves for the two randomized groups. The curves would allow readers to examine the pattern of event-free survival throughout follow-up rather than relying solely on one summary estimate.
The analysis would then typically report an appropriate relative effect measure, such as a hazard ratio with its confidence interval, together with a formal comparison if prespecified. Absolute estimates at clinically relevant time points could complement the relative measure.
Curve
Shows the estimated progression-free survival distribution over time and makes censoring and follow-up patterns more visible.
Effect estimate
A hazard ratio can summarize relative event rates under a Cox model, provided the model is appropriate.
Confidence interval
Quantifies statistical uncertainty around the estimated treatment effect under the specified inferential framework.
Absolute perspective
Time-specific progression-free survival estimates can make the magnitude of the observed difference easier to understand clinically.
20. Statistical Interpretation vs Clinical Interpretation
Statistical interpretation
The study uses randomized allocation and a parallel two-arm design, with progression-free survival from enrollment registered as the primary efficacy endpoint over 3 years. The appropriate statistical framework is therefore a randomized time-to-event comparison.
Clinical interpretation
The clinical meaning of any observed difference would depend on the magnitude and precision of the progression-free survival effect, the pattern of events over time, treatment exposure, and the broader clinical context.
Keeping these interpretations separate is important. Statistical significance, if demonstrated, would address evidence against a specified null hypothesis. Clinical importance requires consideration of the magnitude of the effect and what that magnitude means for patients and clinical practice.
21. Important Limitations and Interpretation Issues
- No posted statistical analyses: the ClinicalTrials.gov record does not contain a formal statistical analysis for the registered primary endpoint.
- No posted efficacy estimates: numerical treatment-effect estimates for progression-free survival are not reported in the registry information summarized here.
- Open-label design: the registry specifies no masking, which can matter for aspects of trial conduct and outcome assessment.
- Endpoint definition: the registry describes the primary endpoint as progression-free survival from enrollment but does not provide the detailed operational event and censoring rules in the summarized record.
- Analysis specifications: the registry information does not identify a particular hypothesis-testing procedure, Cox-model specification, alpha level, multiplicity strategy, or interim-analysis boundary.
- Missing-data rules: detailed methods for incomplete assessments or other missing information are not specified in the summarized registry information.
- Analysis populations: detailed definitions for efficacy and safety populations are not provided in the summarized record.
- Arm-specific numerical data: the registry identifies two arms and intervention components but does not provide arm-specific sample sizes in the information summarized here.
22. Reading a Future Hazard Ratio Correctly
A hazard ratio below 1 would indicate a lower estimated instantaneous rate of progression or death in the numerator group relative to the denominator group under the fitted survival model. It would not mean that the same percentage of patients experienced a corresponding reduction in absolute risk.
A confidence interval containing 1 would indicate that the data are compatible with hazard-ratio values on both sides of the conventional no-difference value under the specified confidence framework. The interpretation would depend on the prespecified hypothesis and analysis plan.
A relatively narrow interval would indicate greater statistical precision around the estimated hazard ratio than a wider interval, although precision is not the same as clinical importance.
A small p-value would provide evidence against the specified null hypothesis under the test used. It would not quantify the size of the treatment effect, the probability that the treatment is beneficial, or the probability that the null hypothesis is true.
23. Broader Statistical Lessons
The primary endpoint of VALENTINO demonstrates several recurring principles in clinical-trial biostatistics.
| Lesson | Statistical meaning |
|---|---|
| Define the estimand first | The endpoint's event definition, time origin, population, and follow-up framework determine what treatment effect is being estimated. |
| Use time-to-event methods for time-to-event data | Kaplan-Meier and related methods preserve information about the timing of events and censoring. |
| Separate relative from absolute effects | A hazard ratio and a survival probability at a particular time are complementary rather than interchangeable. |
| Interpret uncertainty explicitly | Confidence intervals communicate the precision of estimated treatment effects. |
| Respect the analysis plan | Hypothesis testing, censoring, multiplicity, and analysis populations should be prespecified rather than reconstructed after seeing results. |
| Do not equate p-values with clinical importance | Statistical evidence and clinical relevance are different dimensions of interpretation. |
24. Sources
- ClinicalTrials.gov record: NCT02476045.
- PubMed record: PubMed 31539295.
- PubMed record: PubMed 31268481.
Continue through the Clinical Biostats clinical-trial library
Explore additional clinical trial analyses and statistical methods across randomized clinical research.
25. Record Summary
VALENTINO is a phase 2 randomized, parallel, open-label trial enrolling 224 participants with RAS wild-type, metastatic colorectal cancer. The ClinicalTrials.gov record identifies two arms and a primary efficacy endpoint of progression-free survival from enrollment over a 3-year time frame. Statistically, the trial provides a clear example of why randomized treatment comparisons involving time-to-event outcomes require attention to the time origin, event definition, censoring, analysis population, effect measure, uncertainty, and hypothesis-testing framework.
The most appropriate educational framework is therefore to view progression-free survival as a distribution of event times rather than a simple proportion. Kaplan-Meier estimation can describe that distribution, a log-rank framework can compare randomized groups, and a Cox model can provide a hazard-ratio summary when its assumptions are appropriate. None of these methods, however, removes the need to define the estimand and prespecify the analysis rules.